 Miriam Post
Concepts (333)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stillbirth | 2 | 2024 | 57 | 1.750 |
Why?
| | Placenta | 9 | 2024 | 628 | 1.610 |
Why?
| | Ovarian Neoplasms | 12 | 2023 | 388 | 1.280 |
Why?
| | Uterine Neoplasms | 6 | 2019 | 73 | 1.270 |
Why?
| | Carcinosarcoma | 5 | 2018 | 17 | 1.170 |
Why?
| | Clinical Competence | 3 | 2022 | 893 | 0.890 |
Why?
| | Fetal Death | 1 | 2023 | 50 | 0.890 |
Why?
| | Pathologists | 3 | 2017 | 15 | 0.790 |
Why?
| | Endometrial Neoplasms | 6 | 2023 | 141 | 0.780 |
Why?
| | Education, Medical, Continuing | 1 | 2022 | 117 | 0.740 |
Why?
| | Cystadenocarcinoma, Serous | 4 | 2022 | 44 | 0.640 |
Why?
| | Microfilament Proteins | 1 | 2017 | 126 | 0.550 |
Why?
| | Hemangioma, Capillary | 1 | 2015 | 13 | 0.480 |
Why?
| | Autopsy | 2 | 2024 | 84 | 0.450 |
Why?
| | Lymph Nodes | 4 | 2018 | 419 | 0.440 |
Why?
| | Carrier Proteins | 1 | 2017 | 695 | 0.440 |
Why?
| | Fetus | 3 | 2024 | 700 | 0.430 |
Why?
| | Pre-Eclampsia | 2 | 2021 | 165 | 0.430 |
Why?
| | Immunohistochemistry | 8 | 2023 | 1629 | 0.390 |
Why?
| | Pathology | 3 | 2017 | 20 | 0.380 |
Why?
| | Female | 49 | 2024 | 59523 | 0.380 |
Why?
| | Pregnancy | 10 | 2024 | 5520 | 0.370 |
Why?
| | Fetal Growth Retardation | 2 | 2021 | 468 | 0.350 |
Why?
| | Biomarkers, Tumor | 9 | 2023 | 1040 | 0.340 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2022 | 60 | 0.340 |
Why?
| | Humans | 56 | 2024 | 114709 | 0.330 |
Why?
| | Prognosis | 10 | 2023 | 3330 | 0.330 |
Why?
| | Osteoblastoma | 1 | 2008 | 2 | 0.320 |
Why?
| | Prolactinoma | 1 | 2008 | 11 | 0.320 |
Why?
| | Skull Base | 1 | 2008 | 39 | 0.310 |
Why?
| | Skull Base Neoplasms | 1 | 2008 | 24 | 0.310 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2008 | 52 | 0.300 |
Why?
| | Cytomegalovirus | 1 | 2009 | 144 | 0.300 |
Why?
| | Peritoneal Neoplasms | 3 | 2014 | 54 | 0.290 |
Why?
| | Fetal Diseases | 1 | 2009 | 147 | 0.290 |
Why?
| | Lymphatic Vessels | 2 | 2018 | 54 | 0.280 |
Why?
| | Pituitary Neoplasms | 1 | 2008 | 157 | 0.280 |
Why?
| | Uterus | 3 | 2022 | 192 | 0.280 |
Why?
| | Professionalism | 2 | 2017 | 14 | 0.280 |
Why?
| | Gestational Age | 4 | 2024 | 760 | 0.280 |
Why?
| | Cytomegalovirus Infections | 1 | 2009 | 180 | 0.270 |
Why?
| | Receptors, Estrogen | 5 | 2017 | 372 | 0.270 |
Why?
| | Diagnosis, Differential | 5 | 2019 | 1342 | 0.260 |
Why?
| | Infant, Newborn | 4 | 2024 | 5047 | 0.250 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2022 | 859 | 0.250 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2009 | 288 | 0.240 |
Why?
| | Interleukin-6 | 2 | 2021 | 676 | 0.240 |
Why?
| | Education, Medical, Graduate | 4 | 2017 | 368 | 0.230 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2021 | 216 | 0.230 |
Why?
| | Hypertension, Pulmonary | 1 | 2015 | 1729 | 0.220 |
Why?
| | Internship and Residency | 3 | 2017 | 926 | 0.220 |
Why?
| | Neoplasm Invasiveness | 6 | 2018 | 442 | 0.220 |
Why?
| | Neoplasm Staging | 5 | 2019 | 1167 | 0.210 |
Why?
| | Middle Aged | 20 | 2023 | 26738 | 0.210 |
Why?
| | Lung Neoplasms | 2 | 2015 | 2177 | 0.210 |
Why?
| | Endodermal Sinus Tumor | 1 | 2022 | 7 | 0.210 |
Why?
| | Choriocarcinoma | 1 | 2022 | 8 | 0.210 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 126 | 0.210 |
Why?
| | Fallopian Tubes | 1 | 2022 | 29 | 0.210 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2023 | 68 | 0.210 |
Why?
| | Dendritic Cell Sarcoma, Follicular | 1 | 2022 | 2 | 0.210 |
Why?
| | Carcinoma, Endometrioid | 2 | 2022 | 46 | 0.210 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2023 | 309 | 0.210 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2021 | 577 | 0.200 |
Why?
| | Specialty Boards | 1 | 2022 | 32 | 0.200 |
Why?
| | Antigens, CD | 2 | 2015 | 442 | 0.190 |
Why?
| | Hysterectomy | 3 | 2022 | 106 | 0.190 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 62 | 0.190 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2021 | 9 | 0.190 |
Why?
| | Cell Line, Tumor | 10 | 2023 | 2711 | 0.190 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2019 | 1143 | 0.190 |
Why?
| | Certification | 1 | 2022 | 89 | 0.190 |
Why?
| | beta Catenin | 2 | 2023 | 219 | 0.190 |
Why?
| | Granulosa Cells | 1 | 2021 | 29 | 0.190 |
Why?
| | Ovary | 1 | 2022 | 191 | 0.190 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2023 | 638 | 0.190 |
Why?
| | Ovarian Follicle | 1 | 2021 | 61 | 0.190 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2022 | 194 | 0.180 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 111 | 0.180 |
Why?
| | Decidua | 2 | 2012 | 23 | 0.180 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2023 | 439 | 0.180 |
Why?
| | Neovascularization, Physiologic | 1 | 2021 | 173 | 0.170 |
Why?
| | Adult | 20 | 2023 | 30554 | 0.170 |
Why?
| | Phthalazines | 1 | 2019 | 38 | 0.160 |
Why?
| | Leiomyosarcoma | 1 | 2019 | 26 | 0.160 |
Why?
| | Endometrium | 2 | 2022 | 60 | 0.160 |
Why?
| | Estrogens | 2 | 2012 | 312 | 0.160 |
Why?
| | Leiomyoma | 1 | 2019 | 44 | 0.160 |
Why?
| | Histocompatibility Antigens | 1 | 2019 | 98 | 0.160 |
Why?
| | Gene Expression Profiling | 4 | 2019 | 1518 | 0.160 |
Why?
| | Antineoplastic Agents | 2 | 2023 | 1879 | 0.160 |
Why?
| | Up-Regulation | 1 | 2021 | 808 | 0.150 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2019 | 96 | 0.150 |
Why?
| | Adenocarcinoma | 2 | 2015 | 795 | 0.150 |
Why?
| | Diverticulum | 1 | 2018 | 11 | 0.150 |
Why?
| | Uterine Diseases | 1 | 2018 | 14 | 0.150 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2018 | 14 | 0.150 |
Why?
| | Premature Birth | 1 | 2021 | 276 | 0.150 |
Why?
| | Fetal Blood | 2 | 2021 | 270 | 0.150 |
Why?
| | Extracellular Matrix | 1 | 2021 | 436 | 0.140 |
Why?
| | Piperazines | 1 | 2019 | 309 | 0.140 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2017 | 38 | 0.140 |
Why?
| | Retinopathy of Prematurity | 1 | 2018 | 111 | 0.140 |
Why?
| | Blood Vessels | 1 | 2018 | 180 | 0.140 |
Why?
| | Cisplatin | 2 | 2015 | 262 | 0.130 |
Why?
| | Cell Proliferation | 5 | 2015 | 2187 | 0.130 |
Why?
| | Employment | 1 | 2017 | 137 | 0.130 |
Why?
| | Job Satisfaction | 1 | 2017 | 168 | 0.130 |
Why?
| | Endothelial Cells | 1 | 2021 | 687 | 0.130 |
Why?
| | Breast Neoplasms | 3 | 2012 | 1862 | 0.130 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2015 | 28 | 0.130 |
Why?
| | Receptors, Progesterone | 3 | 2015 | 319 | 0.130 |
Why?
| | Pelvic Neoplasms | 1 | 2015 | 18 | 0.130 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2015 | 34 | 0.130 |
Why?
| | Mutation | 2 | 2023 | 3346 | 0.130 |
Why?
| | Keratin-5 | 1 | 2015 | 46 | 0.120 |
Why?
| | Oxidative Stress | 1 | 2021 | 1076 | 0.120 |
Why?
| | Skin Neoplasms | 2 | 2012 | 756 | 0.120 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2015 | 27 | 0.120 |
Why?
| | Tuberous Sclerosis | 1 | 2015 | 36 | 0.120 |
Why?
| | Incidental Findings | 1 | 2015 | 70 | 0.120 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 138 | 0.120 |
Why?
| | Capillaries | 1 | 2015 | 91 | 0.120 |
Why?
| | Educational Measurement | 1 | 2016 | 243 | 0.120 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2019 | 699 | 0.120 |
Why?
| | Chest Pain | 1 | 2015 | 81 | 0.120 |
Why?
| | Mesothelioma, Cystic | 1 | 2014 | 1 | 0.120 |
Why?
| | Sarcoma | 1 | 2016 | 137 | 0.120 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2014 | 34 | 0.120 |
Why?
| | Carcinoma | 1 | 2016 | 198 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1140 | 0.110 |
Why?
| | Chorioamnionitis | 1 | 2014 | 36 | 0.110 |
Why?
| | Lymphatic Metastasis | 4 | 2018 | 275 | 0.110 |
Why?
| | Cough | 1 | 2015 | 107 | 0.110 |
Why?
| | Glycoproteins | 1 | 2015 | 304 | 0.110 |
Why?
| | Survival Rate | 4 | 2018 | 1644 | 0.110 |
Why?
| | Fertility Preservation | 1 | 2014 | 46 | 0.110 |
Why?
| | Accreditation | 1 | 2014 | 76 | 0.110 |
Why?
| | Adenomyosis | 1 | 2013 | 1 | 0.110 |
Why?
| | Interleukin-8 | 1 | 2014 | 237 | 0.110 |
Why?
| | Robotics | 1 | 2014 | 75 | 0.110 |
Why?
| | Dyspnea | 1 | 2015 | 211 | 0.110 |
Why?
| | Fatigue | 1 | 2015 | 294 | 0.110 |
Why?
| | Gestational Trophoblastic Disease | 1 | 2012 | 5 | 0.110 |
Why?
| | Neural Stem Cells | 1 | 2014 | 115 | 0.110 |
Why?
| | Menstrual Cycle | 1 | 2013 | 108 | 0.100 |
Why?
| | Luteinizing Hormone | 1 | 2013 | 169 | 0.100 |
Why?
| | Infertility | 1 | 2013 | 45 | 0.100 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2012 | 25 | 0.100 |
Why?
| | Lectins | 1 | 2012 | 42 | 0.100 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2012 | 53 | 0.100 |
Why?
| | Aged | 11 | 2023 | 19074 | 0.100 |
Why?
| | Carcinoma, Lobular | 1 | 2012 | 44 | 0.100 |
Why?
| | Neoplastic Stem Cells | 1 | 2015 | 329 | 0.100 |
Why?
| | Interleukin-1beta | 1 | 2014 | 370 | 0.100 |
Why?
| | United States | 4 | 2022 | 12186 | 0.100 |
Why?
| | Antibodies, Neoplasm | 1 | 2012 | 30 | 0.100 |
Why?
| | Cicatrix | 1 | 2012 | 50 | 0.100 |
Why?
| | Endometriosis | 1 | 2012 | 40 | 0.100 |
Why?
| | Lymph Node Excision | 3 | 2018 | 139 | 0.100 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2011 | 14 | 0.100 |
Why?
| | Apoptosis | 4 | 2015 | 2363 | 0.100 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 2 | 2023 | 31 | 0.100 |
Why?
| | Paclitaxel | 1 | 2012 | 190 | 0.100 |
Why?
| | DNA Polymerase II | 2 | 2023 | 37 | 0.100 |
Why?
| | Nervous System Diseases | 1 | 2014 | 256 | 0.090 |
Why?
| | Leptin | 1 | 2012 | 210 | 0.090 |
Why?
| | Diagnostic Errors | 1 | 2012 | 149 | 0.090 |
Why?
| | Bridged-Ring Compounds | 1 | 2011 | 9 | 0.090 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2011 | 23 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2012 | 195 | 0.090 |
Why?
| | Trophoblastic Neoplasms | 1 | 2010 | 2 | 0.090 |
Why?
| | Carcinoma, Large Cell | 1 | 2010 | 14 | 0.090 |
Why?
| | Retrospective Studies | 8 | 2018 | 12556 | 0.090 |
Why?
| | Neoplasms, Squamous Cell | 1 | 2010 | 4 | 0.090 |
Why?
| | Skin Diseases | 1 | 2012 | 122 | 0.090 |
Why?
| | Taxoids | 1 | 2011 | 93 | 0.090 |
Why?
| | Cesarean Section | 1 | 2012 | 169 | 0.090 |
Why?
| | B7-H1 Antigen | 2 | 2022 | 139 | 0.090 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2010 | 29 | 0.090 |
Why?
| | Graft vs Host Disease | 1 | 2012 | 212 | 0.090 |
Why?
| | Peptides | 1 | 2015 | 848 | 0.090 |
Why?
| | Biological Evolution | 1 | 2014 | 416 | 0.090 |
Why?
| | Inflammation | 2 | 2018 | 2480 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 975 | 0.090 |
Why?
| | Genital Neoplasms, Female | 1 | 2010 | 70 | 0.080 |
Why?
| | Biopsy | 3 | 2022 | 1036 | 0.080 |
Why?
| | Amniocentesis | 1 | 2009 | 21 | 0.080 |
Why?
| | Africa, Eastern | 1 | 2009 | 10 | 0.080 |
Why?
| | Fever of Unknown Origin | 1 | 2009 | 7 | 0.080 |
Why?
| | Neoplasm Grading | 2 | 2019 | 242 | 0.080 |
Why?
| | Infarction | 1 | 2008 | 12 | 0.080 |
Why?
| | Prolactin | 1 | 2008 | 96 | 0.080 |
Why?
| | Homeodomain Proteins | 1 | 2012 | 463 | 0.080 |
Why?
| | Blood Chemical Analysis | 1 | 2008 | 90 | 0.080 |
Why?
| | Viremia | 1 | 2009 | 122 | 0.070 |
Why?
| | Travel | 1 | 2009 | 121 | 0.070 |
Why?
| | Models, Statistical | 1 | 2011 | 599 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2023 | 445 | 0.070 |
Why?
| | Headache | 1 | 2008 | 133 | 0.070 |
Why?
| | Surveys and Questionnaires | 2 | 2017 | 4624 | 0.070 |
Why?
| | Neoplasm Proteins | 1 | 2010 | 385 | 0.070 |
Why?
| | Immunoglobulin M | 1 | 2009 | 246 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2012 | 520 | 0.070 |
Why?
| | Ultrasonography, Prenatal | 1 | 2009 | 236 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2021 | 3004 | 0.070 |
Why?
| | Mice | 7 | 2021 | 14872 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2018 | 182 | 0.070 |
Why?
| | MicroRNAs | 1 | 2012 | 600 | 0.070 |
Why?
| | Disease Progression | 3 | 2019 | 2381 | 0.070 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2018 | 332 | 0.070 |
Why?
| | Survival Analysis | 2 | 2021 | 1211 | 0.060 |
Why?
| | Mice, Nude | 3 | 2012 | 630 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2018 | 4411 | 0.060 |
Why?
| | Animals | 9 | 2021 | 31709 | 0.060 |
Why?
| | Prospective Studies | 3 | 2023 | 6220 | 0.060 |
Why?
| | Immunoglobulin G | 1 | 2009 | 770 | 0.060 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 37 | 0.050 |
Why?
| | Activating Transcription Factor 6 | 1 | 2023 | 16 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1356 | 0.050 |
Why?
| | Brain | 1 | 2014 | 2371 | 0.050 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 80 | 0.050 |
Why?
| | Lung | 1 | 2015 | 3561 | 0.050 |
Why?
| | Ultrasonography | 2 | 2018 | 634 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2013 | 3053 | 0.050 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2021 | 24 | 0.050 |
Why?
| | Mice, SCID | 2 | 2012 | 314 | 0.050 |
Why?
| | Maternal Age | 1 | 2021 | 117 | 0.050 |
Why?
| | Cervix Uteri | 1 | 2021 | 45 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2022 | 177 | 0.050 |
Why?
| | Young Adult | 4 | 2021 | 10472 | 0.050 |
Why?
| | Open Reading Frames | 1 | 2021 | 117 | 0.050 |
Why?
| | Ligands | 1 | 2022 | 562 | 0.050 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 78 | 0.040 |
Why?
| | Estradiol | 2 | 2013 | 455 | 0.040 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2019 | 17 | 0.040 |
Why?
| | Cell Division | 1 | 2021 | 758 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2008 | 2286 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 387 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2019 | 57 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 32 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2021 | 399 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 1796 | 0.040 |
Why?
| | Fetal Development | 1 | 2021 | 248 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 76 | 0.040 |
Why?
| | Cytoskeletal Proteins | 1 | 2019 | 145 | 0.040 |
Why?
| | Pregnancy, Tubal | 1 | 2018 | 5 | 0.040 |
Why?
| | Ovarian Cysts | 1 | 2018 | 8 | 0.040 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 18 | 0.040 |
Why?
| | Salpingectomy | 1 | 2018 | 13 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 1 | 2019 | 174 | 0.040 |
Why?
| | Pelvic Pain | 1 | 2018 | 32 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 140 | 0.040 |
Why?
| | Frozen Sections | 1 | 2018 | 24 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2023 | 6347 | 0.040 |
Why?
| | Risk Factors | 3 | 2018 | 8634 | 0.040 |
Why?
| | Abortion, Spontaneous | 1 | 2018 | 90 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 386 | 0.040 |
Why?
| | Phosphorylation | 1 | 2021 | 1569 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 869 | 0.030 |
Why?
| | Abortion, Induced | 1 | 2018 | 71 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 4895 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 633 | 0.030 |
Why?
| | Ifosfamide | 1 | 2016 | 32 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 345 | 0.030 |
Why?
| | Faculty | 1 | 2017 | 130 | 0.030 |
Why?
| | AC133 Antigen | 1 | 2015 | 19 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 726 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 48 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2637 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2019 | 551 | 0.030 |
Why?
| | Risk | 1 | 2018 | 812 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1737 | 0.030 |
Why?
| | Cell Count | 1 | 2015 | 303 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1694 | 0.030 |
Why?
| | Histones | 1 | 2019 | 535 | 0.030 |
Why?
| | Fellowships and Scholarships | 1 | 2017 | 227 | 0.030 |
Why?
| | Male | 4 | 2017 | 55609 | 0.030 |
Why?
| | Receptors, Androgen | 1 | 2015 | 131 | 0.030 |
Why?
| | Peritoneal Cavity | 1 | 2014 | 23 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 620 | 0.030 |
Why?
| | Laparoscopy | 1 | 2018 | 398 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2012 | 2553 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1373 | 0.030 |
Why?
| | Follicular Phase | 1 | 2013 | 36 | 0.030 |
Why?
| | Luteal Phase | 1 | 2013 | 41 | 0.030 |
Why?
| | Hysteroscopy | 1 | 2013 | 9 | 0.030 |
Why?
| | Primates | 1 | 2014 | 111 | 0.030 |
Why?
| | Organ Size | 1 | 2014 | 436 | 0.030 |
Why?
| | Oocytes | 1 | 2014 | 170 | 0.030 |
Why?
| | Cryopreservation | 1 | 2014 | 92 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2019 | 1019 | 0.030 |
Why?
| | Vaginal Neoplasms | 1 | 2012 | 11 | 0.030 |
Why?
| | Karyotyping | 1 | 2012 | 102 | 0.030 |
Why?
| | Anoikis | 1 | 2012 | 31 | 0.030 |
Why?
| | Mothers | 1 | 2018 | 651 | 0.030 |
Why?
| | Cell Survival | 1 | 2015 | 1021 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 797 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2012 | 113 | 0.020 |
Why?
| | Tamoxifen | 1 | 2012 | 191 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2014 | 796 | 0.020 |
Why?
| | Perioperative Period | 1 | 2011 | 49 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2012 | 176 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 259 | 0.020 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2011 | 44 | 0.020 |
Why?
| | Tubulin | 1 | 2012 | 123 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2012 | 181 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 3408 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2012 | 432 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 555 | 0.020 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2010 | 26 | 0.020 |
Why?
| | Cell Cycle Checkpoints | 1 | 2011 | 84 | 0.020 |
Why?
| | Adolescent | 1 | 2008 | 17855 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2010 | 57 | 0.020 |
Why?
| | Transfection | 1 | 2012 | 866 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2010 | 192 | 0.020 |
Why?
| | Mitosis | 1 | 2011 | 164 | 0.020 |
Why?
| | Organ Specificity | 1 | 2010 | 268 | 0.020 |
Why?
| | HeLa Cells | 1 | 2011 | 562 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 945 | 0.020 |
Why?
| | Microtubules | 1 | 2011 | 237 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2010 | 740 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 923 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1147 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 993 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 4410 | 0.020 |
Why?
| | Cytokines | 1 | 2014 | 1841 | 0.020 |
Why?
| | Chronic Disease | 1 | 2012 | 1578 | 0.020 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2012 | 534 | 0.020 |
Why?
| | Infant | 1 | 2018 | 7964 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2540 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2016 | 9088 | 0.010 |
Why?
| | Signal Transduction | 1 | 2011 | 4516 | 0.010 |
Why?
|
|
Post's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|